S. aureus carriage
Conditions
Interventions
After inclusion and determination of carrier status, all volunteers will be
treated with Mupirocin (Bactroban) 2% nasal ointment and Chlorhexidine
gluconate (Hibiscrub®) 4% cutaneous body wash solut
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Volunteers must be over 18 years old
Exclusion criteria
Exclusion criteria: - Employee of the Erasmus MC - Intermittent carrier of Staphylococcus aureus - Use of drugs influencing microbiome in 3 months prior to the study period i.e. antibiotics, antiparasitics or antifungals - Regular use of commercial probiotics in 3 months prior to the study period - Known allergy to components of the intervention treatment (see Ch 5.1) - Pregnant and breastfeeding women, due to limited scientific evidence on adverse effects of mupirocin treatment during pregnancy and breastfeeding. - Known chronic diseases affecting the immune system (such as diabetes mellitus, renal insufficiency, COPD, heart diseases, immunocompromised status (HIV, AIDS), skin diseases such as severe eczema or use of immunosuppressant drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microbiome composition of the nose, to be analysed in relation to S. aureus carrier status and decolonization. | — |
Countries
Netherlands
Outcome results
None listed